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Toxoplasma gondii is a protozoan parasite that persists as a chronic infection. Toxoplasma evades immunity by forming tissue
cysts, which reactivate to cause life-threatening disease during immune suppression. There is an urgent need to identify drugs
capable of targeting these latent tissue cysts, which tend to form in the brain. We previously showed that translational control is
critical during infections with both replicative and latent forms of Toxoplasma. Here we report that guanabenz, an FDA-ap-
proved drug that interferes with translational control, has antiparasitic activity against replicative stages of Toxoplasma and the
related apicomplexan parasite Plasmodium falciparum (a malaria agent). We also found that inhibition of translational control
interfered with tissue cyst biology in vitro. Toxoplasma bradyzoites present in these abnormal cysts were diminished and mis-
configured, surrounded by empty space not seen in normal cysts. These findings prompted analysis of the efficacy of guanabenz
in vivo by using established mouse models of acute and chronic toxoplasmosis. In addition to protecting mice from lethal doses
of Toxoplasma, guanabenz has a remarkable ability to reduce the number of brain cysts in chronically infected mice. Our find-
ings suggest that guanabenz can be repurposed into an effective antiparasitic with a unique ability to reduce tissue cysts in the
brain.
According to the Centers for Disease Control and Prevention,over 60 million people in the United States may be infected
with the intracellular protozoan parasite Toxoplasma gondii. In
other regions of the world, seroprevalence has been estimated to
be as high as 80% (1). This apicomplexan parasite has obtained
such an extensive distribution among humans and other animals
through its multiple routes of transmission (2). Toxoplasma can
be spread by inhalation or ingestion of oocysts expelled by infected
felines, the definitive host of the parasite. Upon infection, the rep-
licative phase of the parasite (tachyzoite) converts into a more
quiescent phase (bradyzoite) as intracellular tissue cysts, which
can facilitate further spread of the parasite if ingested by a preda-
tor. Unfortunately, Toxoplasma is also capable of crossing the pla-
cental barrier, making mother-to-child infection yet another
mode of transmission for the parasite. Between 400 and 4,000
cases of congenital toxoplasmosis occur in the United States each
year, which can result in severe birth defects that include vision
impairment and neurological effects (3).
Most infections with Toxoplasma are asymptomatic due to the
host immune response, quickly prompting transformation of the
parasite from the tachyzoite stage to the latent bradyzoite stage.
The bradyzoites form tissue cysts, which constitute a chronic in-
fection that the host is thought to retain for life. Severe health risks
arise when the immunity of an infected individual becomes im-
paired, which can occur in AIDS patients, triggering conversion of
the bradyzoites into rapidly replicating tachyzoites (2). Reactiva-
tion of infection results in an episode of acute toxoplasmosis that
can be life-threatening and necessitates treatment with drugs,
such as the antifolate regimen of pyrimethamine and sulfadiazine
(4). Currently, there is no approved therapy that eradicates the
tissue cysts responsible for chronic infection, and the untoward
side effects of antifolates severely limit their utility in patients. In
short, new therapies that can target both the tachyzoite and bra-
dyzoite stages are urgently needed.
We previously suggested that translational control through
phosphorylation of parasite eukaryotic initiation factor 2
(eIF2) is important for the development and maintenance of
latent forms of Toxoplasma and another apicomplexan parasite,
Plasmodium (a malaria agent) (5, 6). eIF2 is a well-conserved fac-
tor that delivers initiator tRNA to ribosomes during protein syn-
thesis (7). Upon cellular stress, the alpha subunit of eIF2 is phos-
phorylated, curbing general protein synthesis coincident with
preferential translation of a subset of mRNA transcripts that are
involved in stress amelioration (7, 8). Our previous studies of
Toxoplasma established that TgIF2 phosphorylation is critical
during the lytic cycle in tachyzoites and also occurs in response to
stresses that induce conversion of tachyzoites to bradyzoites in
vitro (9–11). Since translational control has roles in both of these
clinically relevant parasite stages, TgIF2 phosphorylation is a
process that shows great promise as a novel antiparasitic drug
target. To address this idea, we showed that inhibitors of eIF2
dephosphorylation, namely, guanabenz and salubrinal, have
potent activity against Toxoplasma in vitro (12).We further dem-
onstrated that these drugs could act directly on the parasite to
maintain TgIF2 phosphorylation and that their ability to kill
Toxoplasma did not involve host eIF2 (10, 12). The anti-Toxo-
plasma activity of guanabenz is also promising because this drug is
already FDA approved, with a proven safety record that goes back
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30 years (13). Importantly, guanabenz also crosses the blood-
brain barrier (14), which is an important criterion for drug can-
didates, since bradyzoite tissue cysts have a propensity to form in
the brain.
In the present study, we determined the activity of guanabenz
against additionalToxoplasma strains aswell as the fellow apicom-
plexan parasite Plasmodium falciparum in vitro, noting that gua-
nabenz exhibits a unique ability to disrupt tissue cyst physiology.
We further addressed the efficacy of guanabenz against both acute
and chronic stages of infection by using establishedmousemodels
of toxoplasmosis. Consistent with the in vitro data, guanabenz not
only protects mice from acute toxoplasmosis but also reduces the
number of brain cysts in chronically infected animals. These re-
sults suggest that guanabenzmay rapidly be repurposed as a novel
antiparasitic agent that can dually target replicative and latent
stages of the parasite.
MATERIALS AND METHODS
Chemical reagents. Guanabenz acetate was purchased from Sigma-Al-
drich (G110) and dissolved in saline at a concentration of 2.5 mg/ml for
storage at 20°C. Salubrinal was synthesized in collaboration with the
Department of Chemistry and Chemical Biology, Indiana University–
Purdue University at Indianapolis, with the assigned standard nomencla-
ture IUSC-12447-000-A, and was stored at 20°C. Salubrinal was dis-
solved to 10mg/ml in dimethyl sulfoxide (DMSO) andwasmade fresh for
each use.
Parasite culture and replication assays.Toxoplasmaparasites (strains
ME49 and Prugniaud [Pru] BSG-4) (15) weremaintained in human fore-
skin fibroblast (HFF) monolayers in Dulbecco’s medium supplemented
with 10% heat-inactivated fetal bovine serum (FBS), 100 U/ml penicillin,
and 100 g/ml streptomycin. Uninfected and infected HFF cells were
maintained in a humidified incubator at 37°C with 5% CO2.
To monitor Toxoplasma replication, a standard parasite counting as-
say was used (16). Briefly, 104 Pru parasites were allowed to infect a con-
fluent HFF monolayer. At 4 h postinfection, extracellular parasites were
removed and the medium was replaced with medium containing the in-
dicated concentration of drug or vehicle. At 32 h postinfection, parasites
were fixed with 1 ml ice-cold methanol for 10 min and then stained with
Diff-Quick (Siemens) for 1 min to visualize parasites by light microscopy
(17). The number of tachyzoites in each of 50 randomly chosen vacuoles
was recorded.
P. falciparum strains HB3 (Honduras) and Dd2 (Indochina) were
maintained in O human red blood cells (Biochemed, Winchester, VA)
and RPMI 1640 medium (Gibco) supplemented with 0.5% Albumax II
(Gibco), 0.25% sodium bicarbonate (Corning), and 0.01mg/ml gentami-
cin (Gibco) under an atmosphere of 90% nitrogen, 5% O2, and 5% CO2.
Cultures underwent at least two life cycles prior to initiation of assays to
ensure that normal growth was established. Dose-response curves were
generated using a hypoxanthine incorporation assay (18). Briefly, parasite
cultures for assays were maintained as asynchronous cultures and re-
quired to reach a parasitemia of no less than 1%, with 70% of parasites in
the early ring stage. Sample parasitemia and hematocrit were then ad-
justed to 0.2% and 2%, respectively, and the samples were added to test
plates containing 2-fold dilutions of guanabenz. Parasites were exposed to
drug dilutions for 48 h. [3H]hypoxanthine (PerkinElmer) was added to
the plates and incubated for an additional 20 h before freezing at80°C
for 24 h. Plate contents were harvested and counted on a Trilux beta
counter. The dose-response curves show means for three independent
biological replicates.
In vitro bradyzoite differentiation assays. Toxoplasma tachyzoites
were converted into bradyzoite tissue cysts in vitro by using previously
described methods (19), with minor modifications. Approximately 0.5
106 parasites were allowed to infect 12- to 14-day-old HFF monolayers
cultured in T-25 flasks under the normal conditions described above.
Four hours later, infected cells were washed to remove parasites that had
not invaded host cells, and an alkaline medium was applied (pH 8.1).
Flasks were kept in a humidified incubator at 37°Cwith ambient CO2, and
the alkaline mediumwas replaced every other day. To visualize cyst walls,
flasks were fixed with 4% paraformaldehyde in phosphate-buffered saline
(PBS) and stained with rhodamine-conjugated Dolichos biflorus aggluti-
nin (Vector Laboratories).
In vivo assays.Acute and chronic toxoplasmosis was studied in vivo by
using female BALB/c mice of 4 to 6 weeks of age (Harlan Laboratories)
that were maintained at the Indiana University School of Medicine ac-
cording to institutional and IACUC guidelines. To study acute infection,
mice were injected intraperitoneally (i.p.) with a lethal dose of tachyzoites
(104 ME49 tachyzoites or 106 Pru tachyzoites). The indicated dose of
guanabenz or saline vehicle was injected i.p. every 2 days, starting at 24 h
postinfection. Mice were monitored at least twice a day, and the time to
death was recorded. To establish chronic infection, mice were inoculated
with a nonlethal dose of 105 Pru parasites.Onday 25 postinfection, chron-
ically infected mice were randomized and administered guanabenz or
saline vehicle (i.p.) for 19 days, a treatment time based on previous studies
(e.g., see reference 20). For each mouse experiment, a portion of the par-
asite inoculum was used in a standard plaque assay; the plaque-forming
efficiencies verified that there were no significant fitness differences be-
tween the parasites in the inoculums.
To determine cyst burdens, brains were homogenized in PBS, and a
portion of each was analyzed to enumerate cysts or parasite burdens as
described previously (21). For cyst counts, brain homogenates were fixed
with 3%methanol-free formaldehyde (Thermo Scientific) for 20min and
blocked in 0.2%TritonX-100with 3.0%bovine serum albumin (BSA) for
1 h. Cysts were visualized by staining with rhodamine-conjugated Doli-
chos biflorus lectin. For measurements of parasite burden, total genomic
DNAs were isolated from brain homogenates by using DNeasy blood and
tissue kits (Qiagen), and the Toxoplasma B1 gene was measured by quan-
titative PCR (qPCR) with the following primers: sense, 5=-GGAGGACT
GGCAACCTGGTGTCG; and antisense, 5=-TTGTTTCACCCGGACCGT
TTAGCAG (22). The number of parasites was deduced from a standard
curve prepared in parallel.
RESULTS
Guanabenz inhibits replicative stages of Toxoplasma and Plas-
modium in vitro. We previously showed that guanabenz inhibits
in vitro replication of the type I RH and type II ME49 strains of
Toxoplasma (12). In preparation to assess the impact of guana-
benz on in vivo models of toxoplasmosis, we expanded in vitro
testing to measure the effect of guanabenz on type II Prugniaud
(Pru) parasites. For these studies, we selected a modified version
of Pru containing a green fluorescent protein (GFP) reporter
downstream of the LDH2 bradyzoite promoter, which provides a
convenient means to monitor stage switching (15). Consistent
with previous studies of strains RH and ME49 (12), guanabenz
significantly inhibited replication of the Pru strain at concentra-
tions as low as 1M,with a 50% effective concentration (EC50) of
6 M (Fig. 1A). We also determined if guanabenz could inhibit
the growth of other apicomplexan parasites, such as Plasmodium
falciparum, a causative agent of severe malaria. Using a conven-
tional hypoxanthine incorporation assay (23), we found that gua-
nabenz inhibited both strains HB3 (chloroquine sensitive) and
Dd2 (chloroquine resistant), with EC50s of 4.2 M and 5.7 M,
respectively (Fig. 1B). Together, these studies show that guana-
benz not only has activity against multiple Toxoplasma genetic
backgrounds but also impedes replication of other apicomplexan
parasites.
Guanabenz and salubrinal affect bradyzoite cysts generated
in vitro. We previously found that guanabenz and salubrinal in-
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hibited the reactivation of latent bradyzoites in vitro, but whether
the drug treatment perturbed Toxoplasma cyst morphology was
not determined (12). To investigate this question, tissue cysts were
induced in HFF monolayers by using alkaline pH and CO2 star-
vation for 6 days, at which point 15 M guanabenz or 8 M
salubrinal was applied for 3 days (Fig. 2A). Inspection of drug-
treated flasks revealed a subset of cysts that exhibited unusual
morphologies under light microscopy. In sharp contrast to the
densely packed and tightly organized bradyzoites present in nor-
mal cysts, some of the drug-treated cysts contained fewer, more
loosely organized bradyzoites and an unusual amount of empty
space (Fig. 2B). Additionally,Dolichos staining of the cyst wall was
less robust in the abnormal cysts, indicating a degradation of cyst
structures. To quantitate this phenomenon, 200 random cysts
were examined and scored as normal or abnormal. Flasks treated
with vehicle or pyrimethamine never displayed any abnormal
cysts, but 4% and 15% of cysts were abnormal in the guanabenz-
and salubrinal-treated flasks, respectively. Attempts were made to
amplify this effect by increasing the concentrations of guanabenz
and salubrinal or the treatment duration, but this appeared to be
detrimental to host cells. These results suggest that both guana-
benz and salubrinal dually target tachyzoites and bradyzoites in
vitro.
Guanabenz protects mice acutely infected with a lethal dose
of Toxoplasma. Based on our in vitro findings, we sought to de-
termine whether TgIF2 dephosphorylation inhibitors func-
tioned against toxoplasmosis in vivo. We focused on guanabenz
for these studies because it is already an FDA-approved drug and
has excellent solubility and much better penetration into the cen-
tral nervous system (CNS) than that of salubrinal (24, 25). Previ-
ously, we reported that guanabenz extends the life of BALB/cmice
acutely infected with a lethal dose of hypervirulent RH strain
tachyzoites: mice that normally succumb to infection by day 7
survived an additional 3 to 4 days when treatedwith the drug (12).
Whether guanabenz is also effective against type II strains had not
yet been determined. We therefore determined whether adminis-
tration of guanabenz also promotes survival of mice infected with
theME49 or Pru strain. BALB/cmice were infected with a lethal
dose of Pru or ME49 tachyzoites and administered guanabenz
at 5 or 10 mg/kg of body weight or given the saline vehicle (Fig.
3). Drug treatment was initiated at 24 h postinfection and ad-
ministered again every 48 h. Guanabenz prolonged the survival
of mice infected with 106 Pru tachyzoites by 2 to 3 days, in a
dose-dependent fashion (Fig. 3A). One hundred percent of
mice infected with 104 ME49 tachyzoites and receiving the ve-
hicle control succumbed to infection by day 9, but those treated
with guanabenz displayed enhanced survival in a dose-depen-
dent fashion (Fig. 3B). Sixty percent of infected mice receiving
the higher dose of guanabenz survived the lethal inoculum of
Toxoplasma ME49.
Reducedcystburdens inmice treatedwithguanabenzduring
acute infection. Since type II strains readily form bradyzoites, a
possible explanation for the protective effects of guanabenz could
be enhanced tissue cyst formation in vivo. To address this possi-
bility, we infected BALB/c mice with a sublethal dose of Pru strain
tachyzoites and administered guanabenz (5mg/kg/day) or vehicle
for 19 days. Brain tissue cysts were visualized usingDolichos lectin
staining and were enumerated as previously described (21). In the
representative experiment shown in Fig. 4A, a 78% reduction of
brain cysts was found in mice treated with guanabenz relative to
those treated with vehicle. This experiment was repeated three
independent times with similar results. In addition, we assessed
the parasite burden in the brain by using qPCR to measure the
Toxoplasma B1 gene DNA (22). Again, significantly fewer para-
sites were detected in mice receiving the guanabenz treatment
(Fig. 4B).
Guanabenz reduces cyst burdens in chronically infected
mice. Our experiments suggested that treatment with guanabenz
can significantly lower the number of Toxoplasma tachyzoites in
vivo without causing an increase in brain cyst burden. We next
addressed whether guanabenz can affect brain cysts present in
chronically infected mice. BALB/c mice were infected with a sub-
lethal dose of Pru strain tachyzoites and allowed to develop
chronic infection, with no drugs being administered. At day 25
postinfection, the chronically infectedmicewere treatedwith gua-
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FIG 1 Guanabenz has potent activity against apicomplexan parasites in vitro.
(A) Guanabenz inhibits the replication of the type II Prugniaud (Pru) strain in
vitro. Tachyzoites were allowed to invade an HFF host cell monolayer for 4 h,
atwhich point the uninvaded parasiteswere removed by replacing themedium
with medium containing the indicated concentration of guanabenz or vehicle
(saline). At 32 h postinfection, the numbers of parasites in 50 random vacuoles
were determined and plotted as the percentages of the vacuoles containing the
numbers of parasites shown (2, 4, 8, 16, etc.). Data represent the averages for 3
independent experiments. Statistical analysis was performed using the un-
paired t test (*, P 0.05; **, P 0.01; ***, P 0.001). Error bars represent the
averages and standard deviations for 3 independent experiments. (B) Guana-
benz inhibits the replication of two independent strains of Plasmodium falcip-
arum in vitro (Dd2 and HB3). Dose-response curves show the means for three
biological replicates. The y axis shows the percent growth relative to that of
vehicle controls, and the x axis shows the log of the concentration of guanabenz
(GA).
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nabenz (5 mg/kg/day) or vehicle for 19 days, at which point the
brains were harvested and tissue cysts counted. Strikingly, a sig-
nificant reduction in cyst burden was found in the guanabenz-
treated mice. Brains from the chronically infected mice receiving
vehicle contained 900 cysts, whereas those from guanabenz-
treated mice contained only 300 cysts, representing a 69% re-
duction in the number of cysts (Fig. 5). Similar reductions in the
number of brain cysts were observed in drug-treatedmice in three
independent experiments. We concluded that treatment with
guanabenz reduces the number of brain cysts in chronically in-
fected mice.
DISCUSSION
New drugs are urgently needed to treat infections caused by api-
complexan parasites, such as Toxoplasma and Plasmodium. These
parasites have complex life cycles that involve stages of latency and
replication. In the case of Toxoplasma, latent bradyzoite tissue
cysts thwart efforts to fully eradicate the infection from patients.
An ideal drug should not only be effective against the prolifer-
ative stage of the parasite but also exert dual activity against the
tissue cyst stage. We previously showed that translational con-
trol via the phosphorylation of TgIF2 is critical during both
the tachyzoite and bradyzoite stages and is also important in
various aspects of Plasmodium physiology (9, 10, 26, 27). These
findings suggest that pharmacological interference in transla-
tional control through parasite eIF2 may serve as a broad-
spectrum strategy that targets multiple life cycle stages of dif-
ferent pathogens.
Two established inhibitors of TgIF2 dephosphorylation, gua-
nabenz and salubrinal, have been shown to inhibit Toxoplasma
replication and to impede the reconversion of bradyzoites into
tachyzoites in vitro (12). In the present study, we significantly
extended these findings to an in vivo context by usingmousemod-
els of acute and chronic toxoplasmosis. The present study focused
on guanabenz for in vivo studies, as guanabenz is already an FDA-
approved drug and has excellent solubility and much better pen-
etration into the CNS than that of salubrinal (24, 25). Our results
show that guanabenz not only protects mice from acute toxoplas-
mosis but also reduces the number of brain cysts in chronically
infected animals.When in vitro-generated tissue cystswere treated
with TgIF2 dephosphorylation inhibitors, the appearance of the
bradyzoites was dramatically altered and the intensity of the cyst
wall staining was diminished. No overt changes appeared in the
host cells at these concentrations.
Concentrations of guanabenz are significantly higher in the
brains of rats and mice than in the plasma (24), which is a likely
FIG 2 Impacts of guanabenz and salubrinal on in vitro bradyzoite cysts. (A) Schematic representation of the experiment. Pru strain bradyzoite cysts were
generated using alkaline medium and CO2 starvation for 6 days. On day 6, guanabenz (GA), salubrinal (SAL), or vehicle (DMSO, the solvent for salubrinal) was
added to the cultures, and tissue cysts were evaluated 3 days later. (B) Representative images of in vitro-generated cysts. The LDH2-GFP reporter (green)was used
to visualize bradyzoites, and Dolichos biflorus lectin (DB; red) stain was used to observe cyst walls. Tz, tachyzoite; Bz, bradyzoite.
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contributing factor to the ability of the drug to reduce brain cysts.
One study found that, on average,2 M guanabenz can be de-
tected in the brains of mice at 2 to 4 h postinjection (28), which
corresponds to the concentration that we found to inhibit Toxo-
plasma proliferation in vitro (Fig. 1A). These findings are consis-
tent with previous results showing that guanabenz and salubrinal
can act directly on Toxoplasma to prevent TgIF2 dephosphory-
lation and that the antiparasitic activities of these drugs do not
involve host eIF2 (12). However, it remains possible that guana-
benz can affect host cell processes, such as those involving immu-
nity, in ways that contribute to the observed activities against the
parasite in vivo. Guanabenz was originally identified as an 2-
adrenergic receptor agonist and has been used to treat hyperten-
sion for decades (29). More recently, guanabenz was shown to
protect human cells from protein misfolding stress by binding to
PPP1R15A/GADD34, thereby inhibiting eIF2 dephosphoryla-
tion (30). GADD34 is a regulatory subunit of the PP1 protein
phosphatase complex that returns eIF2 to its unphosphorylated
state. Interestingly, while guanabenz can clearly block TgIF2 de-
phosphorylation in a dose-dependent manner (12), there is no
clear GADD34 gene orthologue evident in apicomplexan genome
sequences. The precise mechanism by which guanabenz impairs
TgIF2dephosphorylation is an important issue to resolve in light
of the findings presented here.
Guanabenz (Wytensin) dosing for human patients taking the
drug for hypertension scales from an initial dose of 4 mg orally
twice a day to 8 mg orally twice a day, and patients typically use a
maintenance dose of 4 to 16 mg orally twice a day. The maximum
dose studied is 32 mg twice a day. While it is generally well toler-
ated, guanabenz is metabolized by the liver and should be used
with caution in patients with liver impairment, and it should be
noted that safety has not been established for patients of less than
18 years of age. The results reported here for mice show potent
antiparasitic effects at a dose of 5 mg/kg once a day. While there
are important caveats to consider for extrapolating human equiv-
alent doses (HED) from animal studies (31), the HED for 5mg/kg
guanabenz in mice is 0.4 mg/kg, which is within the tolerated
range of 0.07 to 0.53 mg/kg (4 to 32 mg given twice a day) for a
60-kg adult.
We also report here for the first time that guanabenz inhibits
the replication of both chloroquine-sensitive and chloroquine-
resistant strains of P. falciparum in vitro, further highlighting the
potential of guanabenz as a novel antiparasitic agent. Collectively,
our study validates translational control mechanisms as viable
new drug targets for treatment of apicomplexan infections.
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FIG 3 Efficacy of guanabenz (GA) for treatment of infection with a lethal
dose of a Toxoplasma type II strain. (A) BALB/c mice were infected i.p. with
a lethal dose (106) of type II Pru strain tachyzoites. Beginning 24 h later,
guanabenz at 5 mg/kg or 10 mg/kg or vehicle (saline) was administered by
i.p. injection, and this was repeated every 2 days. (B) BALB/c mice were
infected with a lethal dose (104) of type II ME49 strain tachyzoites. Begin-
ning 24 h later, the following treatments were administered and repeated
every 2 days: guanabenz at 5mg/kg or 10mg/kg or vehicle (saline). For both
panels, n 	 3 for each group.
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FIG 4 Toxoplasma-infected mice treated with guanabenz during acute infec-
tion have fewer brain cysts. Forty BALB/c mice were infected i.p. with a non-
lethal dose (105) of Pru strain tachyzoites and randomized for subsequent
treatments. Twenty mice were given guanabenz at 5 mg/kg/day, and the other
20 were treated with vehicle for 19 days, at which point brains were harvested
so parasite burdens could be determined. Serological analyses confirmed in-
fection in all mice, and 5 mice per group were randomly selected for analysis.
(A) Direct counts of the number of cysts per brain in guanabenz-treated mice
versus vehicle-treatedmice. (B) qPCR analysis of infected brain samples, using
the Toxoplasma B1 gene as an indicator of parasite burden. Statistical analysis
was performed using the unpaired t test. Error bars represent the averages and
standard deviations for cyst burden or parasite burden among the mice exam-
ined (n 	 5 per group). Data shown are representative of 3 independent ex-
periments that produced similar results.
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Because it is already FDA approved, guanabenz could rapidly
be repurposed as an antiparasitic; however, newer derivatives
of salubrinal and guanabenz are under intense investigation
and should also be examined for activity against parasites. Very
recently, a new guanabenz derivative, sephin 1, was described
to be a potent inhibitor of eIF2 dephosphorylation (32). Se-
phin 1 lacked any measurable 2-adrenergic agonist activity in
a cell-based assay, which may prove to be advantageous during
prolonged treatment of parasite infection.
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FIG 5 Guanabenz reduces the number of cysts in mice chronically infected
with Toxoplasma. Ten BALB/cmice were infected i.p. with 105 Pru tachyzoites
and allowed to progress to the chronic stage of disease for 25 days. On day 25,
mice were randomized and divided into two groups, one receiving guanabenz
at 5mg/kg/day (n	 5) and the other receiving vehicle (n	 5). After 19 days of
treatment, brains were harvested and cyst numbers determined. Serological
analyses confirmed that all mice were infected. Data from a single representa-
tive experiment are shown, and two independent repeats produced similar
results. Statistical analysis was performed using the unpaired t test, and error
bars represent the averages and standard deviations for cyst burdens among
the mice examined.
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